secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001104659-26-036870
Event type: litigation
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance settles YUPELRI patent suit; generic license start April 23, 2039
----------------------------------------------------------------------------

- Settlement with Mankind Pharma resolves Hatch-Waxman litigation over YUPELRI (revefenacin) ANDA.
- Royalty-free license granted for generic version on or after April 23, 2039, subject to customary exceptions.
- All pending Hatch-Waxman litigation relating to YUPELRI now resolved; settlement subject to DOJ/FTC review.
- Involves patents 11,484,531, 12,048,692 and 12,285,417; parties include Theravance subsidiaries and Mylan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926036870/0001104659-26-036870-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926036870/tm2610626d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-036870

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer